BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Collaboration

  The Top 7 Biopharma Licensing Deals of 2024

  Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their pipelines with novel and potentially more effective therapies.

  February 5, 2025

   · 

  8 min read

   · 

  Tristan Manalac
• 

  Leadership

  Biotech CEO Sisterhood Fills ‘Unmet Need’ for Fellowship Among Women Leaders

  At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of women and allies in biopharma as their authentic selves.

  February 5, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Opinion

  Pharma M&A Uptick Ushers in a New Era of Data Integration

  M&A was already on the upswing in 2024, and the new Trump administration may support that trend. But if data aren’t handled properly, acquisitions won’t reach their full potential.

  February 5, 2025

   · 

  4 min read

   · 

  Raj Indupuri
• 

  Podcast

  RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market

  Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the non-opioid painkiller space heats up as FDA approves Vertex’s Jounavx.

  February 5, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Earnings

  Pipeline Problems Mar Amgen’s Q4 Beat

  Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.

  February 5, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Executive appointments

  Women Leaders Decline in Biotech’s Era of ‘Proven Leadership’

  Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a BioSpace analysis. This is happening in an era of biotech where new company founders are searching for CEOs with a track record.

  February 5, 2025

   · 

  8 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite

  Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

  February 5, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Business

  Valerio Shutters U.S. Operations, Cuts Clinical Work Due to ‘Financing Challenges’

  Valerio only has cash to last three months, according to the DNA decoy specialist. The news comes less than six months after the company acquired Emglev Therapeutics to advance antibodies for autoimmune and inflammatory conditions, as well as cancers.

  February 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Editorial

  A Lack of Women in Leadership Is the Biopharma Story That Never Ends

  BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea brewing. Unfortunately, it was one she’s written before.

  February 5, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Earnings

  GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025

  Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised 2031 sales projections to just over $50 billion.

  February 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac